Arii Daisuke, Ikeno Yohei, Murooka Kunihiko, Nojima Michio, Kidokoro Akio
Dept. of Pharmacy,Juntendo University Urayasu Hospital.
Gan To Kagaku Ryoho. 2012 Apr;39(4):593-7.
Oxaliplatin (L-OHP), a platinum-containing antineoplastic agent, is a key drug for the treatment of colorectal cancer. However, it is often difficult to continue with its treatment because of the expression of allergic reactions. This study was an investigation of the expression of allergic reactions resulting from administration of L-OHP. A retrospective analysis was performed on patients undergoing therapeutic regimens including L-OHP, from April 2009 to November 2010 in Juntendo University Urayasu Hospital. The results showed that allergic reactions were expressed in 15 out of 81 patients (18. 5%). A high correlation was found between the time from administration until expression of the allergic reaction, and the number of treatment courses (r=-0. 521, p=0. 047). When patient characteristics were compared between the allergic reaction group and the no-reaction group, it was suggested that differences due to the regimen or the presence or absence of liver metastasis, which is considered to be related to drug metabolism, had no effect. Items showing significant differences were sexual difference(p=0. 022)and the effect of changes depending on the dose form of L-OHP(p=0. 003). It was possible to continue treatment with L-OHP in six patients even after expression of allergic reactions. Anti-allergy measures such as additional administration of steroids or antihistamines were suggested to be useful for continuing treatment.
奥沙利铂（L-OHP）是一种含铂类抗肿瘤药物，是治疗结直肠癌的关键药物。然而，由于过敏反应的出现，常常难以继续使用该药物进行治疗。本研究旨在调查使用L-OHP后过敏反应的发生情况。对2009年4月至2010年11月在顺天堂大学浦安医院接受包括L-OHP在内治疗方案的患者进行回顾性分析。结果显示，81例患者中有15例（18.5%）出现过敏反应。从给药到出现过敏反应的时间与治疗疗程数之间存在高度相关性（r = -0.521，p = 0.047）。比较过敏反应组和无反应组的患者特征时，发现治疗方案或是否存在被认为与药物代谢有关的肝转移所导致的差异并无影响。显示出显著差异的项目有性别差异（p = 0.022）以及L-OHP剂型变化的影响（p = 0.003）。即使在出现过敏反应后，仍有6例患者能够继续使用L-OHP进行治疗。建议采取额外给予类固醇或抗组胺药等抗过敏措施对继续治疗有效。
